All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2023; the latest 2025-04-30.
From the record
Baird Medical Investment Holdings Ltd's filings since 2023 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-04-30) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-13.7% a year over 4 filed years; profitable in 3 of 4.
From the record
Baird Medical Investment Holdings Ltd's 4 filed years say what it did: revenue went from $35 million in fiscal 2022 to $23 million in fiscal 2025, down 13.7% a year; it rose in 1 of 3 years; the deepest fall was 39% from fiscal 2024 to fiscal 2025; net income was positive in 3 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Baird Medical Investment Holdings Ltd's shareholder treatment is put at 6.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 37% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -88%: lost 88¢ per shareholder dollar. Leverage 55%: owes 55¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Baird Medical Investment Holdings Ltd lost about 88 cents for every dollar of shareholders' money, and gross profitability: its products earned about 27 cents per dollar of everything the company owns. Leverage: it owed about 55 cents per dollar of assets, and net share issuance: its share count grew 27.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 21% of 109 in its family; net margin -122.2%.
From the record
Baird Medical Investment Holdings Ltd's standing among 109 graded names in its industry family: revenue of $23 million in fiscal 2025 ranks in the bottom 30% by size; a net margin of -122.2% ranks in the bottom 23%; revenue growth of -13.7% a year over the last 3 filed years ranks in the bottom 11% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Baird Medical Investment Holdings Ltd's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-27 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 105 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 37% of 104 in its family for room to expand.
From the record
Baird Medical Investment Holdings Ltd's room to grow, from the newest filed statements (fiscal 2025): cash of $566 thousand against debt of $6 million leaves -7.9% of its assets as net cash, bottom 30% of its family; cash from operations less capital spending is -6.2% of revenue (top 50%); a gross margin of 83.8% (top 10%); research spending of 89.3% of revenue (top 17%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 40% of 105 in its family for growth drivers.
From the record
Baird Medical Investment Holdings Ltd's growth drivers, from the filed years to fiscal 2025: revenue grew -13.7% a year over the last three filed years against -13.7% over all 4, speeding up (top 43% of its family); the newest year grew -39.2% (bottom 6%); research spending grew 73.4% a year (top 3%); capital spending grew -80.7% a year (bottom 2%) (its annual reports). Baird Medical Investment Holdings Ltd reported 2 product lines in fiscal 2025: Microwave Ablation Needles at $17 million (76%), Microwave Ablation Therapeutic Apparatus at $5 million (24%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 7% of 88 in its family for expectations against reality.
From the record
Baird Medical Investment Holdings Ltd's newest year against its own record: revenue of $23 million in fiscal 2025 came in 40.8% below the $38 million its prior three years' pace pointed to (bottom 10% of its family); net income of $28 million against a prior three-year average of $12 million (bottom 6%); a net margin of a loss larger than its revenue against 34.8% before (bottom 4%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made